Nexalin Technology

Nexalin Technology Gross Margin

The Gross Margin of Nexalin Technology (NXL) as of Nov 11, 2026 is 79.65 %. In the previous year, Gross Margin was 78.31 % — a change of 1.71% (higher).

Gross Margin

79.65 %

YoY

1.71%

Last updated:

Gross Margin of Nexalin Technology is 2025 79.65 % . Gross Margin of Nexalin Technology was 2024 78.31 % . It decreases by 1.71% higher compared to the previous year.

Nexalin Technology's gross margin stands at 79.7%, down from 85.1% several years earlier.

The Nexalin Technology Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
-5.22 USD
Jan 1, 2020
88.05 USD
Jan 1, 2021
85.12 USD
Jan 1, 2022
72.51 USD
Jan 1, 2023
76.80 USD
Jan 1, 2024
78.31 USD
Jan 1, 2025
79.65 USD
The Nexalin Technology Gross Margin history
YEARGross MarginYoY
79.65 %+1.71%
78.31 %+1.96%
76.80 %+5.92%
72.51 %-14.81%
85.12 %-3.33%
88.05 %-1,786.45%
-5.22 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology, Inc. generates revenue through the sale of its neurostimulation products, specifically the Generation 1 or Gen-1 device, which treats anxiety and insomnia using bioelectronic medical technology without drugs or psychotherapy. The company's products are non-invasive and undetectable, targeting individuals with mental health issues seeking relief without adverse side effects. Nexalin designs clinical trials for Gen-2, aimed at treating substance use disorders, particularly opiate-related issues, chronic pain, Alzheimer’s disease, and dementia, though Gen-2 is not yet commercially available. The firm focuses on medical applications where traditional treatments may be less effective or carry risks. The primary buyers of Gen-1 are patients with anxiety and insomnia who prefer non-pharmacological solutions. The company’s marketing emphasizes the device’s ease of administration and lack of side effects, appealing to those dissatisfied with conventional treatments. Nexalin’s clinical trials for Gen-2 target healthcare providers and institutions treating substance use disorders, Alzheimer’s, and dementia, positioning the product for future market entry in these high-demand segments. The firm’s revenue model relies on direct sales of Gen-1 and anticipated future sales of Gen-2 once clinical trials are completed and regulatory approvals are secured. Nexalin’s products operate through a unique waveform technology that combines varying voltages, currents, electromagnetic fields, and frequencies applied via electrodes on the head. This technology differentiates the company in the medical device market by offering a non-invasive alternative to drug-based therapies. The company’s focus on mental health and neurological conditions aligns with growing demand for innovative, side-effect-free treatments, enabling it to target specific patient segments seeking alternatives to traditional pharmaceuticals. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Gross Margin of Nexalin Technology is 79.65 % in 2025.

Gross Margin of Nexalin Technology changed from 78.31 % to 79.65 %, representing a 1.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Nexalin Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Nexalin Technology

All Key Metrics — Nexalin Technology